ATE237320T1 - Venlafaxinhaltiges arzneimittel mit verlängerter wirkstoffabgabe - Google Patents

Venlafaxinhaltiges arzneimittel mit verlängerter wirkstoffabgabe

Info

Publication number
ATE237320T1
ATE237320T1 AT98956487T AT98956487T ATE237320T1 AT E237320 T1 ATE237320 T1 AT E237320T1 AT 98956487 T AT98956487 T AT 98956487T AT 98956487 T AT98956487 T AT 98956487T AT E237320 T1 ATE237320 T1 AT E237320T1
Authority
AT
Austria
Prior art keywords
venlafax
product containing
extended release
medicinal product
medicinal
Prior art date
Application number
AT98956487T
Other languages
English (en)
Inventor
Deborah Marie Sherman
John Clifton Clark
John Ulrick Lamer
Stephen Andrew White
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25508423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE237320(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE237320T1 publication Critical patent/ATE237320T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98956487T 1997-11-05 1998-11-03 Venlafaxinhaltiges arzneimittel mit verlängerter wirkstoffabgabe ATE237320T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96432897A 1997-11-05 1997-11-05
PCT/US1998/023338 WO1999022724A2 (en) 1997-11-05 1998-11-03 Extended release formulation containing venlafaxin

Publications (1)

Publication Number Publication Date
ATE237320T1 true ATE237320T1 (de) 2003-05-15

Family

ID=25508423

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98956487T ATE237320T1 (de) 1997-11-05 1998-11-03 Venlafaxinhaltiges arzneimittel mit verlängerter wirkstoffabgabe

Country Status (39)

Country Link
EP (1) EP1028718B1 (de)
JP (1) JP2001521892A (de)
KR (1) KR20010031797A (de)
CN (1) CN1278165A (de)
AR (1) AR014012A1 (de)
AT (1) ATE237320T1 (de)
AU (1) AU747978B2 (de)
BG (1) BG104397A (de)
BR (1) BR9813179A (de)
CA (1) CA2305242A1 (de)
CL (1) CL2004001705A1 (de)
CO (1) CO5011060A1 (de)
CZ (1) CZ20001659A3 (de)
DE (1) DE69813602T2 (de)
DK (1) DK1028718T3 (de)
EA (1) EA200000487A1 (de)
EE (1) EE04577B1 (de)
ES (1) ES2196620T3 (de)
GE (1) GEP20043198B (de)
HK (1) HK1029056A1 (de)
HR (1) HRP20000213B1 (de)
HU (1) HU225238B1 (de)
ID (1) ID26317A (de)
IL (1) IL135457A0 (de)
MA (1) MA24691A1 (de)
NO (1) NO20002126L (de)
NZ (1) NZ504460A (de)
PA (1) PA8462501A1 (de)
PE (1) PE128699A1 (de)
PL (1) PL341141A1 (de)
PT (1) PT1028718E (de)
SK (1) SK6472000A3 (de)
SV (1) SV1998000131A (de)
TR (1) TR200001232T2 (de)
TW (1) TW555568B (de)
UA (1) UA77145C2 (de)
UY (2) UY25234A1 (de)
WO (1) WO1999022724A2 (de)
ZA (1) ZA9810081B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1905757A1 (de) * 1999-04-06 2008-04-02 Sepracor Inc. Derivate von Venlafaxin und Verfahren zu ihrer Herstellung und Verwendung
RU2275191C2 (ru) * 1999-05-20 2006-04-27 Элан Корпорейшн, Плс Состоящие из множества частиц фармацевтические составы с контролируемым высвобождением избирательного ингибитора повторного поглощения серотонина
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
EP1451145A1 (de) * 2001-12-05 2004-09-01 Wyeth Neuer kristalliner polymorph von venlafaxin hydrochlorid und verfahren zu seiner herstellung
WO2003050074A1 (en) * 2001-12-13 2003-06-19 Cadila Healthcare Limited Manufacture of venlafaxine hydrochloride and crystalline polymorphs thereof
AU2002217373A1 (en) * 2002-01-03 2003-07-15 Lek Pharmaceutical And Chemical Company D.D. Controlled release pharmaceutical formulation containing venlafaxine
US20030190351A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Extended release venlafaxine formulations
AU2003226751A1 (en) 2002-03-28 2003-10-13 Synthon B.V. Low water-soluble venlafaxine salts
EP1487429A2 (de) * 2002-03-28 2004-12-22 Synthon B.V. Zusammensetzungen von venlafaxin-grundlage
EP1485344A1 (de) 2002-03-28 2004-12-15 Synthon B.V. Venlafaxinbesylat
FR2845289B1 (fr) 2002-10-04 2004-12-03 Ethypharm Sa Spheroides, procede de preparation et compositions pharmaceutiques.
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
DE10350194B4 (de) * 2003-10-28 2005-11-10 Bioplanta Arzneimittel Gmbh Verwendung von Extrakten aus Opuntien zur Behandlung von depressiven Verstimmungen und Erkrankungen
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
DK1502587T3 (da) * 2003-07-30 2007-01-02 Pharmathen Sa Formulering med vedvarende frigivelse af venlafaxinhydrochlorid
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
PT1711169E (pt) 2004-02-04 2007-07-23 Alembic Ltd Minicomprimidos revestidos de libertação prolongada de cloridrato de venlafaxina.
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
JP5349290B2 (ja) * 2006-04-03 2013-11-20 オディディ，イサ 薬物送達組成物およびそれを含む医薬品、ならびにその製造方法
WO2007129329A2 (en) * 2006-05-08 2007-11-15 Jubilant Organosys Limited Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
CN102772390B (zh) * 2012-08-16 2014-01-08 乐普药业股份有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
FR3080278B1 (fr) * 2018-04-11 2021-04-30 Ghs Patents Ltd Procede de fabrication d'un spheroide de cannabidiol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
EE04577B1 (et) 2006-02-15
MA24691A1 (fr) 1999-07-01
GEP20043198B (en) 2004-03-25
AU747978B2 (en) 2002-05-30
BG104397A (en) 2001-02-28
HU225238B1 (en) 2006-08-28
SK6472000A3 (en) 2000-11-07
WO1999022724A2 (en) 1999-05-14
NZ504460A (en) 2003-01-31
CL2004001705A1 (es) 2005-06-03
JP2001521892A (ja) 2001-11-13
CA2305242A1 (en) 1999-05-14
CN1278165A (zh) 2000-12-27
NO20002126L (no) 2000-05-04
AR014012A1 (es) 2001-01-31
HUP0004287A3 (en) 2002-05-28
PE128699A1 (es) 2000-01-06
PA8462501A1 (es) 2000-05-24
EE200000212A (et) 2001-04-16
EP1028718B1 (de) 2003-04-16
HRP20000213B1 (en) 2004-04-30
HK1029056A1 (en) 2001-03-23
DK1028718T3 (da) 2003-07-28
NO20002126D0 (no) 2000-04-26
TR200001232T2 (tr) 2000-12-21
ZA9810081B (en) 2000-05-04
DE69813602D1 (de) 2003-05-22
DE69813602T2 (de) 2003-11-06
CO5011060A1 (es) 2001-02-28
CZ20001659A3 (cs) 2001-10-17
PL341141A1 (en) 2001-03-26
ES2196620T3 (es) 2003-12-16
TW555568B (en) 2003-10-01
HUP0004287A2 (hu) 2002-04-29
HRP20000213A2 (en) 2000-12-31
KR20010031797A (ko) 2001-04-16
EA200000487A1 (ru) 2000-10-30
UY25692A1 (es) 2000-03-31
AU1300399A (en) 1999-05-24
SV1998000131A (es) 1999-11-18
ID26317A (id) 2000-12-14
IL135457A0 (en) 2001-05-20
WO1999022724A3 (en) 1999-07-22
PT1028718E (pt) 2003-07-31
EP1028718A2 (de) 2000-08-23
UA77145C2 (en) 2006-11-15
UY25234A1 (es) 2000-12-29
BR9813179A (pt) 2000-08-22

Similar Documents

Publication Publication Date Title
ATE217794T1 (de) Ranolazinhaltige arzneimittel mit verzögerter wirkstoffabgabe
ATE237320T1 (de) Venlafaxinhaltiges arzneimittel mit verlängerter wirkstoffabgabe
DE69513671T2 (de) Arzneimittel
ATE248594T1 (de) Irbesartanhaltiges arzneimittel
DE122010000011I1 (de) Flüssige gonadotropinhaltige Arzneimittel
ATE240732T1 (de) Ziprasidonhaltige arzneimittel
ATE202472T1 (de) Arzneimittel enthaltend oxaliplatin
ATE138566T1 (de) Tramadol enthaltendes arzneimittel mit verzögerter wirkstoffabgabe
PT862863E (pt) Produto cerealifero contendo probioticos
ATE367150T1 (de) Arzneimittel
DE69224656D1 (de) Arzneimittel
DE69812708T2 (de) Neue arzneimittel enthaltend uridintriphosphat
DE29713884U1 (de) Tablettenspender
DE69709349D1 (de) Arzneimittel bestehend aus diclofenac
ATE219365T1 (de) Arzneimittel enthaltend mizolastin mit verzögerter wirkstoffabgabe
ATE269337T1 (de) Trizyclische delta3-pyridine als arzneimittel
EA199900672A1 (ru) Гомеопатическое лекарственное средство
DE60008237D1 (de) Lamivudin enthaltende arzneimittel
DE29708649U1 (de) Tablettenspender
DE59805373D1 (de) Nephroprotektive Arzneimittel
EA199900673A1 (ru) Гомеопатическое лекарственное средство
DE69819203D1 (de) Trinkbares arzneimittel
DE29720448U1 (de) Stabilisiertes Kombinationsarzneimittel
ATE332709T1 (de) Stabilisiertes arzneimittel enthaltend cysteinylderivate
DE29616221U1 (de) Tablettenspender

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1028718

Country of ref document: EP

RZN Patent revoked